CINECA IRIS Institutional Research Information System
IRIS è la soluzione IT che facilita la raccolta e la gestione dei dati relativi alle attività e ai prodotti della ricerca. Fornisce a ricercatori, amministratori e valutatori gli strumenti per monitorare i risultati della ricerca, aumentarne la visibilità e allocare in modo efficace le risorse disponibili.
EnglishPrimary systemic therapy represents the standard of care for locally advanced breast cancer and has becoming an attractive alternative in earlier stages. A part from the proven advantage of increasing the rate of breast conservative surgery, the up front use of systemic therapy can allow for an in vivo test of treatment sensitivity, and response to primary treatment discriminates patients at different prognosis. This review will summarize the more relevant data on the preoperative treatment with chemotherapy, hormonal therapy and targeted agents. © 2006 Elsevier Ireland Ltd. All rights reserved.
Scheda prodotto non validato
Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo
| Data di pubblicazione: | 2007 | |
| Titolo: | Primary systemic therapy for operable breast cancer: A review of clinical trials and perspectives | |
| Autori: | Guarneri, Valentina; Frassoldati, Antonio; Giovannelli, Simona; Borghi, Francesca; Conte, Pierfranco | |
| Rivista: | CANCER LETTERS | |
| Parole Chiave: | Breast cancer; Primary chemotherapy; Primary endocrine therapy; Primary targeted therapy; Antineoplastic Agents; Breast Neoplasms; Female; Humans; Randomized Controlled Trials as Topic; Oncology; Cancer Research | |
| Abstract in inglese: | Primary systemic therapy represents the standard of care for locally advanced breast cancer and has becoming an attractive alternative in earlier stages. A part from the proven advantage of increasing the rate of breast conservative surgery, the up front use of systemic therapy can allow for an in vivo test of treatment sensitivity, and response to primary treatment discriminates patients at different prognosis. This review will summarize the more relevant data on the preoperative treatment with chemotherapy, hormonal therapy and targeted agents. © 2006 Elsevier Ireland Ltd. All rights reserved. | |
| Digital Object Identifier (DOI): | 10.1016/j.canlet.2006.07.001 | |
| Handle: | http://hdl.handle.net/11392/2377851 | |
| Appare nelle tipologie: | 03.1 Articolo su rivista |
File in questo prodotto:
Copyright © 2022